CF Patient Support Programme Little Miss Fearless
Enhancing Treatment Adherence in Children with Cystic Fibrosis
SITUATION
Children with cystic fibrosis (CF) often struggle to understand the importance of their treatments, leading to challenges in adherence. Initially, parents manage the treatment regimen, but as children grow, they need to assume responsibility. Traditional medical explanations may not resonate with young minds, making it difficult for them to connect their medication intake with improved health outcomes.
APPROACH
To bridge this understanding gap, we employed a comprehensive methodology:
-
Social Listening and Interviews: We conducted in-depth analyses and discussions with children and their parents to understand how they view the role of treatment.
- Experience Mapping: We mapped the patient experience, identifying the pivotal “moments that matter” in their disease and treatment journey.
-
Programme Blueprint: C0-creating with children and parents in workshops, we developed the PSP blueprint for materials, address the behavioural learnings empowering them to better appreciate the role and benefits of treatment.
-
Interactive Educational Tools: We introduced “Little Miss Fearless,” an immersive and interactive journey guiding children through an imaginary body. This adventure, led by the character Molly, helps children visualize how treatments aid in maintaining their health.
OUTCOMES
This patient support programme yielded significant positive results:
-
Enhanced Understanding: When questioned, children could articulate the role of their treatments in preventing exacerbations and reducing hospitalisations.
-
Engagement in Health Management: By experiencing the educational journey, children became more proactive in managing their condition, leading to better health outcomes.
- Improved Treatment Adherence: Anecdotally, parents felt their children demonstrated a notable increase in adherence to their regimen.
By mapping critical moments that matter and blueprint a programme that could address behavioural learnings, we were able to build foundations for how treatment could enable a life less limited by CF.
